Clinical trial
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
NCT01566162
Study timeline
Study start (unknown)2012-04-01Date precision: month
Registry last updated2019-04-09
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Schizophreniaunresolved
Interventions
LurasidoneDRUG · verified · RxNorm: lurasidone
Sponsors & collaborators
Sumitomo Pharma America, Inc.lead sponsor
Mapped research locations
Saint PetersburgRussia3DallasTexas, United States2AtlantaGeorgia, United States2AustinTexas, United States2Little RockArkansas, United States2Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1St LouisMissouri, United States1San DiegoCalifornia, United States1Oklahoma CityOklahoma, United States1RochesterNew York, United States1Salt Lake CityUtah, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01566162 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.